New Promising Data on S&N’s BIRMINGHAM HIP™ System
Link
http://www.ryortho.com/NEWSSHORTS/volume3/issue39/12-10-07-NS-New.htm
By Elizabeth Hofheinz, MEd, MPH December 10, 2007
No more wondering Down Under. The data is in. Smith & Nephew, Inc.’s
Orthopaedic Reconstruction business is announcing the release of positive
six-year clinical data by the Australian Orthopaedic Association National Joint
Replacement Registry on the company’s BIRMINGHAM HIP Resurfacing System (BHR™).
According to the company, the BHR, which has now been implanted in nearly 80,000
patients in 26 countries, conserves more of a patient’s bone than a traditional
hip replacement, enabling younger, more active patients to undergo hip
replacement surgery while preserving all future surgery options, including a
primary hip replacement. The design of the BIRMINGHAM HIP Resurfacing System
also offers patients a reduced risk of dislocation. The report revealed that the
BHR device has the highest hip resurfacing system survivability rate among all
of its established competitors for which data had been collected.
Included in the Australian report was the following information:
Since the inception of the registry, the BIRMINGHAM HIP Resurfacing System has
been the overwhelming choice of patients—over 75% of resurfacing procedures have
used the BHR device.
According to the registry, hip resurfacing accounts for 7.9% of all primary
hip replacements.
Commenting in the news release was Joseph DeVivo, President of Smith &
Nephew Orthopaedic Reconstruction: “We are extremely pleased with the
Registry’s results. The report once again highlights the ability of the
BIRMINGHAM HIP Resurfacing System to help people maintain the most active
and healthy lifestyle possible. The BIRMINGHAM HIP Resurfacing System lets
active people live the life they love and continue to pursue their passions.
The long-term clinical data available clearly demonstrates the benefits of
the BIRMINGHAM HIP Resurfacing System, which is the gold standard for
resurfacing technology in the world and a significant addition to our
reconstructive product portfolio in the United States.”
The Registry evaluates the timing and reasons for revision surgery as well
as mortality rates, and it measures the success rates of products and
procedures across Australia. This year’s report is based on the analysis of
332,700 hip and knee procedures undertaken in 271,188 patients from
September 1999 through December 31, 2006.
According to the company, the study is highly regarded for its
comprehensiveness and accuracy because the Registry is able to obtain a
near-complete set of data relating to hip and knee joint replacement for an
entire country. The Registry receives information from all public and
private hospitals undertaking joint replacement. Using a strict validation
process and following retrieval of unreported records and checking of
unmatched data, the initial validation for the 2005/6 Registry data resulted
in over 96% of Registry records verified against health department data.